Slide 1: Result presentation Q2/2022
4 August 2022, Seppo Kopsala, CEO / Lars Lindqvist, CFO Result presentation Q2/2022
Slide 2: Highlights
Highlights OPT@MED
Slide 3: Highlights Q2 2022
Q2 2022 Revenue decreased by 7.0 percent to EUR 3,7 (4,0) million due to 1. Chinese revenue declining over 90% Highlights Q2 2022 2. Strong software, OEM, and global distributor sales 3. Successful directed share issue raised EUR 4.8 million
Slide 4: Focus areas
Focus areas USA: • Focus area in terms of Optomed’s growth investments: number of sales and marketing personnel hired during the quarter • The FDA clearance process for the Aurora AEYE product is proceeding as planned China: • Previously, Phoebus’ exclusivity terminated & new national guidelines pub
Slide 5: New US Business Model – Subscription
New US Business Model – Subscription In the next 5-10 years, there will be at least 50,000 – 100,000 fundus cameras connected to AI in the US Complete Solution Business Model Customer Benefits From product sales to complete screening solutions with diagnosis Solution leased, not No initial investmen
Slide 6: Q2/2022 Financial highlights (KEUR)
Q1/2022 Financial highlights (KEUR) Q2/2022 Q2/2021 Change Revenue 3,733 4,012 -7.0% Gross profit 1) 2,149 3,324 -35.4% Gross margin 2) 57.6% 82.9% Adjusted EBITDA -813 177 -559.1% Adjusted EBITDA margin -21.8% 4.4% Net profit/ loss -1,328 -864 -53.8% Earnings per share -0.10 -0.06 -48.4% Cash flow
Slide 7: H1/2022 Financial highlights (KEUR)
H1/2022 Financial highlights (KEUR) H1/2022 H1/2021 Change Revenue 6,947 7,956 -12.7% Gross profit 1) 4,339 5,901 -26.5% Gross margin 2) 62.4% 74.2% Adjusted EBITDA -1,750 -138 -1,172% Adjusted EBITDA margin -25.2% -1.7% Net profit/ loss -2,698 -1,480 -82.3% Earnings per share -0.20 -0.11 -76.4% Cas
Slide 8: Devices segment highlights
Devices segment highlights OPT@MED
Slide 9: Devices segment highlights
Q2/2022 Q2/2021 Change Revenue from China decreased 1. over 90% whereas the rest of the world grew over 40% Devices segment highlights Revenue 1,361 1,896 -28.2% Strong OEM and global Gross profit 642 1,811 -64.6% 2. distributor sales growth Gross margin 47.2% 95.5%1) Profitability affected by the E
Slide 10: Software segment highlights
Software segment highlights
Slide 11: Software segment highlights
Q2/2022 Q2/2021 Change A large delivery that was Software segment highlights postponed from Q1 was Revenue 2,372 2,116 12.1% 1. delivered in Q2 which had a positive effect on the quarter Gross profit 1,507 1,513 -0.4% Gross margin 63.5% 71.5% Global screening solution 2. projects continued well in A
Slide 12: Outlook 2022
Outlook 2022 Optomed expects its full year 2022 revenue to grow compared to 2021 (Announced 17 February 2022)
Slide 13: Balance sheet
30 June 2022 30 June 2021 Balance sheet ASSETS Goodwill 4,256 4,256 Development costs 7,115 5,531 • Equity ratio of 63.7 (64.5) percent Other intangible assets 2,215 2,635 Total intangible assets 13,586 12,422 • Total borrowings of EUR 6.3 Total tangible assets 1,707 1,352 (5.8) million. Total non-c
Slide 14: Cash flow
Q2 2022 Q2 2021 Loss for the financial year -1,328 -864 Cash flow Cash flows before change in net working capital -369 -253 Change in net working capital -189 -1,112 • Cash flow from operating activities amounted to EUR -1.0 Cash flows before finance items -557 -1,365 (-1.4) million Cash flows from
Slide 15: Optomed's mission is to prevent blindness by improving access to eye screening globally
Optomed’s mission is to prevent blindness by improving access to eye screening globally Expansion into new Opening new customer Bringing AI-integrated geographical markets segments: primary care health screening to the market
Slide 16: Appendix
Appendix
Slide 17: Devices Segment H1/2022 financials
Devices Segment H1/2022 financials H1/2022 H1/2021 Change % Revenue 2,425 3,343 -27.5% Gross profit 1,283 2,653 -51.7% Gross margin 52.9% 79.4% EBITDA -963 362 -365.8% EBITDA margin -39.7% 10.8%
Slide 18: Software Segment H1/2022 financials
Software Segment H1/2022 financials H1/2022 H1/2021 Change % Revenue 4,522 4,613 -2.0% Gross profit 3,056 3,248 -5.9% Gross margin 67.6% 70.4% EBITDA 898 788 14.0% EBITDA margin 19.9% 17.1%
Slide 19: Cash flow H1/2022
Cash flow H1/2022 H1 2022 H1 2021 Loss for the financial year -2,698 -1,480 Cash flows before change in net working capital -1,273 -465 Change in net working capital 49 -1,157 Cash flows before finance items -1,223 -1,622 Cash flows from finance items -442 -37 Net cash from operating activities -1,6